首页 | 本学科首页   官方微博 | 高级检索  
     


Combination chemotherapy only for stage II non-Hodgkin's lymphoma
Affiliation:1. Department of Surgery, Hartford HealthCare, St. Vincent''s Medical Center, Bridgeport, CT, United States;2. Department of Education, Netter School of Medicine Quinnipiac University, North Haven, CT, United States;3. Department of Pathology, Hartford HealthCare, St. Vincent''s Medical Center, Bridgeport, CT, United States;1. Division of Internal Medicine, University Hospital Basel, Basel, Switzerland;2. Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland;3. Department of Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau, Aarau, Switzerland;4. Department of Clinical Research, University of Basel, Basel, Switzerland
Abstract:
Twenty-six previously untreated patients with clinical stage (CS) II B non-Hodgkin's lymphoma (NHL) were treated with systemic chemotherapy only. Patients received bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP). All patients had intermediate- or high-grade lymphoma. Objective response was demonstrated in 25 patients (96%), with 21 patients (81%) achieving complete remission (CR). Two of CR patients developed unsalvageable relapse, the remaining 19 patients are still alive and disease-free. The median duration of CR has not been reached. Of four patients (15%) with documented partial remission (PR), three were salvaged using second-line therapy. Over a median follow-up of 12 months (range, 3–30), 22 patients (85%) are alive and disease-free, of whom 16 (62%) have survived more than 1 yr. Bulky disease or gastrointestinal tract (GIT) involvement did not influence the CR rate. Our results compared favorably with radiation therapy for stage II NHL; however, a larger controlled and randomized study is warranted.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号